CODEX+ CELIDA Recommendations
1.5.2 - ci-build
CODEX+ CELIDA Recommendations
1.5.2 - ci-build
CODEX+ CELIDA Recommendations - Local Development build (v1.5.2) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Active as of 2022-02 |
{
"resourceType" : "PlanDefinition",
"id" : "TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan",
"meta" : {
"profile" : [
🔗 "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/recommendation-plan"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: PlanDefinition TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan</b></p><a name=\"TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan\"> </a><a name=\"hcTherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan\"> </a><a name=\"TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan-en-US\"> </a><p><b>url</b>: <a href=\"PlanDefinition-TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan.html\">PlanDefinition Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients</a></p><p><b>version</b>: 7.0</p><p><b>name</b>: Therapeutic_Anticoagulation_No_Renal_Function_Impairment</p><p><b>title</b>: Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients</p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/plan-definition-type eca-rule}\">ECA Rule</span></p><p><b>status</b>: Active</p><p><b>experimental</b>: true</p><p><b>subject</b>: <a href=\"EvidenceVariable-PopHospitalisedNonICUCOVID19PatientsWITHHighRisk.html\">Population: Hospitalised COVID-19 patients without the need for intensive care therapy considered high-risk for developing venous thrombosis</a></p><p><b>date</b>: 2022-02</p><p><b>publisher</b>: NUM CODEX+ CELIDA</p><p><b>description</b>: </p><div><p>In hospitalized, non-intensive care patients with COVID-19 and increased risk (e.g., D-dimers ≥ 2 mg/l), therapeutic anticoagulation can be considered if the risk of bleeding is low. Anticoagulation, preferentially with NMH or UFH, can be considered.</p>\n</div><blockquote><p><b>goal</b></p><blockquote><p><b>id</b></p>aPTT-goal</blockquote><p><b>category</b>: <span title=\"Codes:{http://snomed.info/sct 410394004}\">Lab findings surveillance (regime/therapy)</span></p><p><b>description</b>: <span title=\"Codes:\">aPTT value should be > 50 sec.</span></p><h3>Targets</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Measure</b></td><td><b>Detail[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://loinc.org 3173-2}\">aPTT in Blood by Coagulation assay</span></td><td>50.0000001-? sec</td></tr></table></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>goalId</b>: aPTT-goal</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationUFH.html\">Therapeutic Anticoagulation Treatment UFH</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHDalteparin1xd.html\">Therapeutic Anticoagulation Treatment with Dalteparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHDalteparin2xd.html\">Therapeutic Anticoagulation Treatment with Dalteparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHDalteparinTable.html\">Therapeutic Anticoagulation Treatment with Dalteparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHNadroparin.html\">Therapeutic Anticoagulation Treatment with Nadroparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHEnoxaparin1xd.html\">Therapeutic Anticoagulation Treatment with Enoxaparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHEnoxaparin2xd.html\">Therapeutic Anticoagulation Treatment with Enoxaparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHCertoparin.html\">Therapeutic Anticoagulation Treatment with Certoparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationFondaparinux.html\">Therapeutic Anticoagulation Treatment with Fondaparinux</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>goalId</b>: aPTT-goal</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationWArgatra.html\">Therapeutic Anticoagulation Treatment with Argatroban</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 432102000}\">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHTinzaparin.html\">Therapeutic Anticoagulation Treatment with Tinzaparin</a></p></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeCapability",
"valueCode" : "computable"
},
{
"url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeRepresentationLevel",
"valueCode" : "structured"
},
{
"url" : "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-partOf",
"valueCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommendation/therapeutic-anticoagulation"
},
{
"extension" : [
{
"url" : "method",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/cs-action-combination-method",
"code" : "at-least"
}
]
}
},
{
"url" : "threshold",
"valuePositiveInt" : 1
}
],
"url" : "https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/ext-action-combination-method"
}
],
"url" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/intervention-plan/therapeutic-anticoagulation",
"version" : "7.0",
"name" : "Therapeutic_Anticoagulation_No_Renal_Function_Impairment",
"title" : "Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients",
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/plan-definition-type",
"code" : "eca-rule"
}
]
},
"status" : "active",
"experimental" : true,
"subjectCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/population/hospitalised-non-icu-covid19-patients-high-risk",
"date" : "2022-02",
"publisher" : "NUM CODEX+ CELIDA",
"description" : "In hospitalized, non-intensive care patients with COVID-19 and increased risk (e.g., D-dimers ≥ 2 mg/l), therapeutic anticoagulation can be considered if the risk of bleeding is low. Anticoagulation, preferentially with NMH or UFH, can be considered.",
"goal" : [
{
"id" : "aPTT-goal",
"category" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "410394004",
"display" : "Lab findings surveillance (regime/therapy)"
}
]
},
"description" : {
"text" : "aPTT value should be > 50 sec."
},
"target" : [
{
"measure" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "3173-2",
"display" : "aPTT in Blood by Coagulation assay"
}
]
},
"detailRange" : {
"low" : {
"value" : 50.0000001,
"unit" : "sec",
"system" : "http://unitsofmeasure.org",
"code" : "s"
}
}
}
]
}
],
"action" : [
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"goalId" : [
"aPTT-goal"
],
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-UFH-administration"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-dalteparin-administration-1xd"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-dalteparin-administration-2xd"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-dalteparin-administration-table"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-nadroparin-administration"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-enoxaparin-administration-1xd"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-enoxaparin-administration-2xd"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-certoparin-administration"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-fondaparinux-administration"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"goalId" : [
"aPTT-goal"
],
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-argatroban-administration"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "432102000",
"display" : "Administration of substance (procedure)"
}
]
},
"definitionCanonical" : "https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-tinzaparin-administration"
}
]
}
IG © 2021+ Universitätsmedizin Greifswald. Package recommendations.celida.codex.netzwerk-universitaetsmedizin.de#1.5.2 based on FHIR 5.0.0. Generated 2024-08-07
Links: Table of Contents |
QA Report |
Issues |
Submit an issue |
Version History |
|